5th Berlin Conference on IP in Life Sciences
2012-02-17 (09:00 - 18:00)
Monoclonal antibodies are the fastest growing segment within the biotech and pharmaceutical industry. Today, four of the top ten selling blockbusters are antibodies. Industry forecasts see global antibody sales rising to $58bn in 2014. Pharma and biotech companies are investing heavily in developing new antibodies to treat a rising number of diseases.
However, antibody concepts also have their limitations. Reimbursement is becoming increasingly difficult in the light of a high price and cost savings in global health delivery, with forthcoming biosimilars applying pressure on the pricing of antibody therapies. Antibody targets are also limited to the surface of the cell and a growing number of alternative active and passive immune therapies will deliver fresh therapeutic concepts to the doctor’s menu.
This BIOCOM Event is a unique opportunity to gain insight into the strategies of pharma and biotech companies. Leading experts in the field of immune therapies will share their knowledge on how to successfully develop and market new concepts.
Representatives from biotech and pharmaceutical companies, researchers, business developers, clinical trial and marketing experts, as well as investors, advisers and patent lawyers can’t afford to miss this high-level event in the outstanding venue that is the Swiss Embassy in Berlin.
When:
17th February 2012, 9.00-18.00
Where:
Embassy of Switzerland, Otto-von-Bismarck-Allee 4, 10557 Berlin , Germany [map]
Registration fee:
Early Bird Rate: EUR 380,- + 19 % VAT (register until 31. Dec. 2011)
Regular Rate: EUR 480,- + 19 % VAT
Registration and further information: www.biocom.de/events/IP